publication date: Jul. 30, 2015

Schulam to Serve as Interim Director of Yale Cancer Center as Lynch Plans to Step Down 

 

THOMAS LYNCH JR., director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale-New Haven, will leave Yale in August to become chairman and chief executive officer of the Massachusetts General Physicians Organization.

Peter Schulam, professor of urology and chief of Yale’s Department of Urology, will serve as the interim director of Yale Cancer Center and physician-in-chief at Smilow.

Lynch joined Yale Cancer Center as director in 2009 and assumed the role of inaugural physician-in-chief at Smilow, which opened that year. During his tenure, more than 130 scientists and clinicians joined the institutions, new-patient volume grew from 3,500 to 9,000 through key affiliations, and participation in therapeutic clinical trials grew by 325 percent.

The center also renewed its NCI Comprehensive Cancer Center Grant, and joined the NCI’s National Clinical Trials Network and the National Comprehensive Cancer Network.

Schulam joined in 2012 as inaugural chief of the Department of Urology at Yale-New Haven Hospital and chair of the department at Yale School of Medicine, where he has established a multidisciplinary team in urologic oncology. He has implemented a program for MRI-fusion guided biopsy of prostate cancer and leads a research program focused on prostate cancer imaging. In addition, he co-founded the Yale Center for Biomedical and Interventional Technology.

 

KAREN RECKAMP was named medical director for clinical research operations at City of Hope.

In this newly created position, Reckamp will expand her current role as chair of the Cancer Protocol Review and Monitoring Committee. She will also serve as medical director of the Clinical Trials Unit and as coordinating liaison for pharmaceutical contracts, as well as share responsibility for the review and selection of clinical trials within City of Hope.

Reckamp is also co-chair of the institution’s Lung Cancer and Thoracic Oncology Program. She is currently principal investigator for an arm of the NCI-MATCH trial.

Reckamp joined City of Hope in 2007, as assistant professor of medicine in the Department of Medical Oncology & Therapeutics. In 2012, she became associate professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Lung Cancer and Thoracic Oncology Program.

She received her medical doctorate from the University of Chicago Pritzker School of Medicine, and her Master of Science degree from the University of California, Los Angeles, where she also received specialized training in advanced research and clinical research. She completed a fellowship in hematology/oncology at UCLA, and an internship and residency at Barnes-Jewish Hospital in St. Louis.

 

TIMOTHY LASH was named leader of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University.

Andrew Miller will continue to serve as co-leader of the program. Lash succeeds Roberd “Robin” Bostick, who served as leader of the program since 2008.

Lash is a professor of epidemiology in the Emory University Rollins School of Public Health; he joined the university in 2013. His research focuses on molecular biomarkers that predict cancer recurrence. He also is interested in age-related disparities in the quality of cancer care.

Earlier this year, Lash was among a select group that received the Emory 1% Award recognizing faculty whose competitive research grant application is ranked in the first percentile. Lash also serves as the editor-in-chief of Epidemiology. He previously held faculty appointments at Wake Forest University School of Medicine, the University of Aarhus in Denmark, and Boston University’s Schools of Public Health and Medicine.

 

THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT and the Ontario Institute for Cancer Research announced a call for pre-proposals from Canadian academic investigators focused on early-stage technologies.

The two organizations are looking to collaborate on projects that will advance the preclinical development of targeted therapeutics or approaches including small molecules, biologics and cell-based therapies.

Unlike traditional grants, CDRD and OICR will work in partnership with academic investigators to develop collaborative project plans addressing the steps required to advance cancer therapies from the lab to the clinic. Projects will be milestone-driven with clear go/no-go decision points with budgets depending on the scope of the project.

More information on the program can be found on the CDRD website.

Copyright (c) 2020 The Cancer Letter Inc.